News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
The company plans to raise US $ 15 million
HCL will establish a joint centre of excellence (CoE) for Google Cloud with industry subject matter experts and Google Cloud-certified ideapreneurs
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
